在治疗罕见病的“孤儿药”的研发领域,一直活跃着许多新兴的中小型生物技术企业。而现在,随着越来越多的大型制药企业将研发重心转向孤儿药,这个领域呈现出群雄逐鹿的态势(见本期“产经”栏目)。对于我国的制药行业来说,这个领域也充满的着机会,因为在一定意义上来说,大家都处于同一起跑线上。但相比于发达国家日益健全的针对“孤儿药”研发的法规,我国在相关政策和立法上还处于起步阶段,如果不尽快推进相关法规和激励机制的设立,那必将制约中国 Many emerging small and medium-sized biotech companies have been active in the research and development of orphan drugs for the treatment of rare diseases. Now, as more and more large pharmaceutical companies shift their research focus to orphan drugs, the field is showing a crowded spot (see the current issue of the birth certificate). For our country’s pharmaceutical industry, this area is also full of opportunities, because in a certain sense, everyone is on the same starting line. However, compared with the increasingly robust laws and regulations on “orphan medicine” developed in developed countries, our country is still in its infancy in the relevant policies and legislation. If we do not push forward the establishment of relevant laws and regulations and incentive mechanisms as soon as possible, it will certainly constrain China